<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Novartis &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/novartis/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Wed, 18 Sep 2024 17:25:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>Novartis &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Novartis is just not participating within the hype surrounding weight-loss drugs, says CEO</title>
		<link>https://bloggingthree.soflytech.com/2024/09/novartis-is-just-not-participating-within-the-hype-surrounding-weight-loss-drugs-says-ceo/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Wed, 18 Sep 2024 17:25:07 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[hype]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[participating]]></category>
		<category><![CDATA[surrounding]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=15098</guid>

					<description><![CDATA[The CEO of Novartis said on Wednesday that the Swiss pharmaceutical giant doesn&#8217;t plan to take part in the &#8220;hype&#8221; surrounding weight-loss drugs, but would quite concentrate on areas where it may possibly construct a &#8220;unique position.&#8221; Vas Narasimhan told CNBC that the corporate is researching treatments that address the unwanted side effects of weight [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>The CEO of <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Novartis<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    said on Wednesday that the Swiss pharmaceutical giant doesn&#8217;t plan to take part in the &#8220;hype&#8221; surrounding weight-loss drugs, but would quite concentrate on areas where it may possibly construct a &#8220;unique position.&#8221;</p>
<p>Vas Narasimhan told CNBC that the corporate is researching treatments that address the unwanted side effects of weight reduction, but doesn&#8217;t plan to compete directly with leading obesity drug makers. <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-3">Eli Lilly.<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span></p>
<p>&#8220;I think simply following the hype now would not be the right move for Novartis,&#8221; he told CNBC&#39;s &#8220;Squawk Box Europe.&#8221;</p>
<p>&#8220;In the obesity space, we currently have two very established major players and I think future market entrants will have to find something new, a new approach that either relieves the nausea and vomiting or gives patients the opportunity to lose weight and maintain their muscle,&#8221; he said, pointing to ongoing work by Novartis research laboratories in these areas.</p>
</div>
<div role="region" aria-labelledby="Placeholder-ArticleBody-Video-108035665">
<div role="button" tabindex="0" id="Placeholder-ArticleBody-Video-108035665" class="PlaceHolder-wrapper" data-vilynx-id="7000352105" data-test="VideoPlaceHolder">
<div class="InlineVideo-videoEmbed" id="InlineVideo-0" data-test="InlineVideo">
<div class="InlineVideo-wrapper">
<div class="InlineVideo-inlineThumbnailContainer"><img decoding="async" class="InlineVideo-videoThumbnail" src="https://image.cnbcfm.com/api/v1/image/108035666-17266389151726638913-36304064156-1080pnbcnews.jpg?v=1726638914&#038;w=750&#038;h=422&#038;vtcrop=y" alt="Novartis is not participating in the hype surrounding weight-loss drugs, says CEO"><span class="InlineVideo-videoButton"></span><span></span></div>
</div>
</div>
</div>
</div>
<div class="group">
<p>Competition for obesity drugs has increased in recent months, with major players corresponding to <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-4">Roche<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-5">Pfizer<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    The market is predicted to achieve a worth of as much as $200 billion over the subsequent decade.</p>
<p>However, Narasimhan said his company is targeting areas &#8220;where we know we can succeed,&#8221; including treating diseases corresponding to Alzheimer&#39;s, Huntington&#39;s and Parkinson&#39;s, in addition to various cancer therapies.</p>
<p>In particular, he saw a substantial market opportunity within the growing <a href="https://www.novartis.com/research-and-development/technology-platforms/radioligand-therapy" target="_blank" rel="noopener">Radioligand therapies</a> (RLTs), a cancer treatment that attacks cancer cells. To date, the corporate has made two acquisitions and launched two drugs on this area.</p>
<p>&#8220;We believe that over time we can build a $20 billion-plus business in this space and hopefully establish a unique position for ourselves rather than chasing other markets,&#8221; he said.</p>
<p>“These are places where I think we have the right to win,” he added.</p>
<p>His comments come after the corporate <a href="https://www.novartis.com/news/media-releases/fda-approves-novartis-kisqali-reduce-risk-recurrence-people-hrher2-early-breast-cancer" target="_blank" rel="noopener">permit</a> Tuesday from the U.S. Food and Drug Administration for its metastatic breast cancer drug Kisqali to treat patients in earlier stages of the disease.</p>
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-9">Novartis<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    After a temporary upswing on the opening of the session, shares had fallen 0.3 percent by 9:30 a.m. London time on Wednesday.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/105709535-1548869591873rts2cvyt.jpg?v=1548869620&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
